Table 3 Multivariate analysis for prognostic factors
Subject | HR | CI 95% | P value | Reference |
|---|---|---|---|---|
OS | ||||
Pelvic LN metastasis | 0.558 | 0.363–0.858 | 0.008 | No pelvic LN metastasis |
para-aortic LN metastasis | 0.381 | 0.232–0.624 | 0.000 | No para-aortic LN metastasis |
EQD2(point A) | 3.168 | 1.915–5.241 | 0.000 | EQD2 < 90Gy10 |
Concurrent chemotherapy | 1.867 | 1.219–2.861 | 0.004 | < 4 cycles |
DFS | ||||
Pelvic LN metastasis | 0.530 | 0.352–0.800 | 0.002 | No pelvic LN metastasis |
Para- aortic LN metastasis | 0.446 | 0.275–0.722 | 0.001 | No para-aortic LN metastasis |
EQD2(point A) | 3.416 | 2.061–5.664 | 0.000 | EQD2 < 90Gy10 |
HGB | 0.652 | 0.435–0.979 | 0.039 | HGB prior treatment < 110 g/L |
Concurrent chemotherapy | 1.907 | 1.266–2.873 | 0.002 | < 4 cycles |
LCR | ||||
Tumor size | 0.254 | 0.060–1.069 | 0.062 | Tumor≤4 cm |
Para- aortic LN metastasis | 0.354 | 0.172–0.727 | 0.005 | No para-aortic LN metastasis |
EQD2(point A) | 5.925 | 3.019–11.630 | 0.000 | EQD2 < 90Gy10 |
DMFS | ||||
Concurrent chemotherapy | 1.874 | 1.160–3.028 | 0.010 | < 4 cycles |